Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform

finance.yahoo.com · 2026-06-25

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Innoviva, Inc. (NASDAQ:INVA) is one of the most promising stocks on our list. TheFly reported on June 18 that INVA announced the launch of Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral therapies through its proprietary […]

TickrTrends take: Innoviva's launch of Nortiva Bio to develop a long-acting oral drug platform represents a significant capital allocation toward pipeline expansion in the Healthcare sector. With INVA currently assessed as fairly valued by TickrTrends, investors should monitor whether this new subsidiary generates meaningful clinical or commercial progress that could justify valuation expansion or alternatively requires ongoing capital deployment that might pressure near-term returns. The success of this platform initiative will be a key factor in determining whether the current valuation assessment remains appropriate as the company advances these development programs.

Read the full story at finance.yahoo.com →